Overview

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Status:
Terminated

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Imatinib Mesylate
Mitogens